The multiple sclerosis study published in the journal The Lancet found that alemtuzumab significantly reduced the number of attacks or relapses by people with MS.
This result was seen both in patients who had not previously received any treatment and those who have continued to show disease activity while taking an existing treatment for MS.
In one trial with patients who had recently relapsed, new episodes were reduced by 49% more than that achieved by the current standard treatment.
Over a two-year period, 65% of patients on alemtuzumab compared with 47% of patients on interferon did not relapse.
More top news
Radio 2 DJ vents his fury on Twitter after turning up for a flight home and finding it full - even though he had a ticket.
Dramatic video shows migrants in a desperate scramble to get off an overcrowded rubber dinghy on to a rescue vessel in the Mediterranean.
Bristol City Council has been ridiculed after a set of double yellow lines measuring less than a metre long were painted in a street.